iSpecimen (NASDAQ:ISPC) Issues Quarterly Earnings Results

iSpecimen (NASDAQ:ISPC) released its quarterly earnings data on Friday. The company reported ($0.98) earnings per share for the quarter, FiscalAI reports. The company had revenue of $0.15 million for the quarter. iSpecimen had a negative net margin of 1,080.16% and a negative return on equity of 584.65%.

iSpecimen Price Performance

Shares of NASDAQ:ISPC traded down $0.05 during trading on Friday, reaching $2.25. 38,846 shares of the company’s stock traded hands, compared to its average volume of 62,931. iSpecimen has a fifty-two week low of $1.77 and a fifty-two week high of $127.20. The company has a 50-day simple moving average of $2.41 and a 200-day simple moving average of $5.81.

Hedge Funds Weigh In On iSpecimen

A hedge fund recently bought a new stake in iSpecimen stock. Virtu Financial LLC acquired a new stake in iSpecimen Inc. (NASDAQ:ISPC) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund acquired 63,257 shares of the company’s stock, valued at approximately $82,000. Virtu Financial LLC owned approximately 0.65% of iSpecimen at the end of the most recent reporting period. 13.62% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of analysts have recently commented on ISPC shares. Weiss Ratings restated a “sell (e+)” rating on shares of iSpecimen in a research note on Friday, July 17th. Wall Street Zen upgraded iSpecimen to a “sell” rating in a research report on Saturday, May 2nd. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has a consensus rating of “Sell”.

About iSpecimen

iSpecimen, Inc (NASDAQ:ISPC) operates an online life sciences marketplace designed to connect researchers with human biological specimens and associated clinical data. The company’s platform streamlines the sourcing of biospecimens—such as plasma, serum, fresh and frozen tissue, saliva, urine and peripheral blood mononuclear cells (PBMCs)—by matching demand from pharmaceutical, biotechnology, diagnostic and academic organizations with supply from a wide network of clinical sites and biobanks.

Through its on-demand procurement model, iSpecimen provides customized specimen collection and fulfillment services that help accelerate research timelines and improve data quality.